Bolt Biotherapeutics (BOLT) AI Stock Analysis

• Market Cap: $9.90M
• Dividend Yield: N/A
• Average Volume (3M): 29.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: -46.88%
• EPS Growth: 34.83%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.72
• Shares Outstanding: 1,919,441
• 10 Day Avg. Volume: 31,146
• 30 Day Avg. Volume: 29,181
• PEG Ratio: 0.66
• Price to Book (P/B): 7.14
• Price to Sales (P/S): 53.13
• P/FCF Ratio: -6.66
• Enterprise Value/Market Cap: -0.03
• Enterprise Value/Revenue: -0.06
• Enterprise Value/Gross Profit: -0.07
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $41.00
• Price Target Upside: 694.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $5.50 ▲(6.59% Upside)

Bolt Biotherapeutics faces significant financial challenges with ongoing losses and cash flow inefficiencies. The restructuring plan and clinical trial updates provide some hope, but the negative valuation and mixed technical indicators weigh heavily on the stock's outlook.

Positive Factors

Innovative Product Pipeline

The development of BDC-4182 highlights Bolt's commitment to innovation in cancer treatment, potentially leading to significant breakthroughs and long-term growth opportunities.

Extended Cash Runway

Extending the cash runway into 2027 provides Bolt with financial stability to continue its R&D efforts and strategic initiatives, reducing the immediate pressure for additional funding.

Strategic Partnerships

Strategic partnerships provide Bolt with financial support and resources, facilitating accelerated R&D and shared risk, enhancing long-term growth prospects.

Negative Factors

Workforce Reduction

The significant workforce reduction may impact employee morale and operational capacity, potentially hindering innovation and productivity in the long term.

Profitability Challenges

Persistent profitability challenges, indicated by a negative net profit margin, may limit Bolt's ability to reinvest in growth initiatives and achieve sustainable financial health.

Cash Flow Inefficiencies

Ongoing cash flow inefficiencies suggest difficulties in generating sufficient cash from operations, which could constrain Bolt's ability to fund future growth and innovation.

Bolt Biotherapeutics Business Overview & Revenue Model

Company Description

Bolt Biotherapeutics (BOLT) is a biotechnology company focused on developing innovative immuno-oncology therapies that harness the power of the immune system to target and destroy cancer cells. The company specializes in creating proprietary platforms that combine its expertise in antibody engineering with cutting-edge technologies to develop treatments for various types of cancer. Bolt's core products and services include its proprietary Boltbody™ platform, which is designed to enhance the efficacy of cancer therapies by improving the targeting and activation of immune cells.

How the Company Makes Money

Bolt Biotherapeutics generates revenue primarily through the advancement of its proprietary drug candidates and strategic collaborations with pharmaceutical companies. The company's revenue model includes potential milestone payments from partnerships, royalties on future product sales, and funding from government grants and research institutions. Significant partnerships with larger biotech and pharmaceutical firms provide Bolt with financial support and resources to accelerate its research and development efforts, while also enabling shared risk in the development of new therapies. As Bolt progresses its clinical trials and achieves development milestones, it has the potential to unlock additional revenue streams through licensing agreements or partnerships.

Bolt Biotherapeutics Financial Statement Overview

Summary

Bolt Biotherapeutics shows modest revenue growth but continues to face significant profitability challenges with a negative net profit margin. The balance sheet is stable with low debt, but cash flow inefficiencies persist.

Income Statement

Bolt Biotherapeutics shows a modest revenue growth with a 34.3% increase from 2022 to 2023 and a slight decline of 2.4% from 2023 to 2024. However, the company has been experiencing significant losses with a negative net profit margin of -820.7% in 2024. The gross profit margin is stable at 100% for 2024, indicating that cost of goods sold is negligible compared to revenue, but high operational expenses continue to weigh down profitability.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio of 0.44 in 2024, suggesting a conservative leverage approach. However, return on equity remains negative due to consistent losses, indicating inefficiencies in generating returns for shareholders. The equity ratio stands at 57.4%, reflecting a stable financial structure with more than half of its assets funded by equity.

Cash Flow

Operating cash flow remains negative, but improved slightly from -69.5 million in 2023 to -61.3 million in 2024. Free cash flow also increased marginally to -61.3 million, indicating ongoing challenges in cash generation. The operating cash flow to net income ratio of 0.97 suggests that cash flow is closely aligned with net losses, while free cash flow to net income ratio mirrors this trend.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.20M	7.69M	7.88M	5.73M	1.26M	231.00K
Gross Profit	4.48M	7.69M	-53.67M	-67.39M	-74.39M	-40.13M
EBITDA	-42.94M	-66.45M	-74.34M	-88.66M	-91.59M	-48.57M
Net Income	-42.68M	-63.12M	-69.20M	-88.10M	-98.59M	-60.73M
Balance Sheet
Total Assets	65.05M	99.63M	159.78M	227.81M	307.72M	46.54M
Cash, Cash Equivalents and Short-Term Investments	31.91M	47.32M	102.19M	168.89M	186.22M	22.84M
Total Debt	23.59M	25.21M	20.22M	22.61M	24.36M	10.88M
Total Liabilities	32.95M	42.43M	47.04M	56.30M	57.60M	151.49M
Stockholders Equity	32.10M	57.20M	112.74M	171.51M	250.12M	-104.95M
Cash Flow
Free Cash Flow	-47.20M	-61.33M	-69.73M	-78.46M	-59.40M	-50.57M
Operating Cash Flow	-47.12M	-61.29M	-69.53M	-76.50M	-57.07M	-47.31M
Investing Cash Flow	55.46M	57.58M	71.04M	57.86M	-232.20M	-20.59M
Financing Cash Flow	43.00K	108.00K	253.00K	503.00K	311.11M	39.60M

Bolt Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Negative. The current price of 5.16 is below the 20-day moving average (MA) of 5.29, below the 50-day MA of 5.32, and below the 200-day MA of 6.07, indicating a bearish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 46.42 is Neutral, neither overbought nor oversold. The STOCH value of 15.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLT.

Bolt Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BOLT	49 Neutral	$9.90M	-0.23	-81.97%	―	-46.88%	34.83%
LYRA	45 Neutral	$6.39M	-0.15	-404.48%	―	-59.21%	68.97%
XBIO	43 Neutral	$4.93M	-1.05	-57.43%	―	13.30%	22.70%
INAB	34 Underperform	$5.61M	-0.18	-189.72%	―	―	70.57%
MBIO	31 Underperform	$7.96M	-0.86	-418.83%	―	―	98.58%

Bolt Biotherapeutics Corporate Events

Bolt Biotherapeutics Announces Major Restructuring Plan

On October 1, 2025, Bolt Biotherapeutics announced a restructuring plan to reduce operating expenses, including a 50% workforce reduction, to extend its cash runway into 2027. The company also provided an update on its Phase 1 study of BDC-4182, observing a strong immune response at initial dose levels and planning to modify the trial protocol for step-up dosing, with initial clinical data expected in the third quarter of 2026.